Key clinical point : A substantial proportion of patients with moderate-to-severe atopic dermatitis (AD) achieved a higher threshold efficacy response ( 90% to <100% improvement in the Eczema Area and Severity Index [EASI-90 to <EASI-100] and EASI-100) with abrocitinib, which subsequently improved their quality of life (QoL).
Major finding: At week 12, a higher proportion of patients receiving 200 mg and 100 mg abrocitinib vs. placebo achieved EASI-90 to <EASI-100 (29.3% and 15.9% vs 5.9%) and EASI-100 (10.7% and 6.0% vs 0%), of which 48.9% and 48.1% vs 33.3% of patients with EASI-90 to <EASI-100 and 67.6% and 63.2% vs 0% of patients with EASI-100 showed QoL benefits.
Study details: Findings are from a post hoc analysis of one phase 2b and two phase 3 ( JADE Mono-1 and JADE Mono-2 ) studies including 942 patients with moderate-to-severe AD and an inadequate response to topical medications who received once-daily 200 mg abrocitinib, 100 mg abrocitinib, or placebo.
Disclosures: This study was sponsored by Pfizer Inc. Four authors declared being employees and shareholders of Pfizer, and other authors reported ties with several sources, including Pfizer.
Source: Stander S et al. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. J Eur Acad Dermatol Venereol. 2022 (Apr 24). Doi: 10.1111/jdv.18170